Open AccessPhamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines
Author(s) -
Wani A. Ahad,
Kar Tahir Ashraf,
Malik latief Ab,
Jawhar Islam,
Aamir Shafi,
Wani Mubashir,
Aleena Ahmad,
Khan Azra,
Dawood Ahmad,
Nayarah Altaf,
Shahid Ahmad
Publication year - 2022
Publication title -
asian journal of medicine and health
Language(s) - English
Resource type - Journals
ISSN - 2456-8414
DOI - 10.9734/ajmah/2022/v20i330444
Subject(s) - covid-19 , pandemic , medicine , demographics , clinical trial , intensive care medicine , disease , infectious disease (medical specialty) , virology , pathology , outbreak , demography , sociology
Coronavirus disease 2019 (COVID-19) has had catestrophic results on the world’s economy and demographics leading to more than 4 million fatalities.This has been the most devastating world crisis after the 1918 pandemic which was caused by influenza. The main concerns regarding the disease have been lack of specific antiviral therapies. Results from recent trials have given some hope and promising results for the treatment of COVID-19 especially Molnupiravir, Monoclonal antibodies and Janus kinase inhibitors. This review article gives a comprehensive update on various pharmacological therapies in the light of recently published standard treatment guidelines based on large clinical trials for the treatment of COVID-19.